Protein Powders

1. 1gov · 2024FDA — Questions and Answers on Dietary Supplements
2. 2label · 2021FDA — Interactive Nutrition Facts Label: Protein (October 2021)
3. 3govUSDA FoodData Central — nutrient data for foods and branded products
4. 4gov · 2023CDC — Physical Activity Guidelines for Adults
5. 5labelDailyMed — RYBELSUS (semaglutide) tablets, prescribing information — Source for the type 2 diabetes and cardiovascular risk-reduction indications, the absence of a weight-management indication, the 3, 7 and 14 mg strengths, and the administration instructions: empty stomach in the morning with up to 4 ounces of water, swallowed whole, waiting at least 30 minutes before food, beverages or other oral medications. Label revised January 2026.
6. 6labelDailyMed — WEGOVY (semaglutide) injection and tablets, prescribing information — Source for the Wegovy tablet indications and the 1.5, 4, 9 and 25 mg strengths, for the tablet administration instructions, for the statement that adverse reaction types and frequencies with the tablets were similar to those with the injection, and for the boxed warning on thyroid C-cell tumors in rodents and the MTC and MEN 2 contraindication. Label revised 6/2026.
7. 7labelDailyMed — FOUNDAYO (orforglipron) tablets, prescribing information — Source for the weight-management indication, the six strengths from 0.8 mg to 17.2 mg, the direction to take one tablet once daily with or without food and to swallow tablets whole, the room-temperature storage, the MTC and MEN 2 contraindication, and the adverse reactions reported in at least 5% of patients. Label revised July 2026.
8. 8labelDailyMed — ZEPBOUND (tirzepatide) injection, prescribing information — Used for the injectable comparison: the adverse reactions reported in at least 5% of patients, and the weight and obstructive sleep apnea indications. Label revised 4/2026.
9. 9govFDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — Source for the standing warning about counterfeit and fraudulent versions of these medications, which is what the affordability gap exposes people to.
10. 10orgBos JD, Meinardi MM — The 500 Dalton rule for the skin penetration of chemical compounds and drugs (Experimental Dermatology, 2000) — Source for the 500-dalton ceiling. The abstract argues molecular weight must be under 500 Da to allow skin absorption, and notes that all topical drugs then used in transdermal drug-delivery systems were under 500 Da. Record confirmed via the EuropePMC REST API (PMID 10839713).
11. 11orgAnnals of Pharmacotherapy (2026) — White CM, Tai Z, Nuzi K, on transdermal dietary-supplement patches marketed under GLP-1 branding (PMID 41480958) — Source for the 24 patch products plus one gel, the average of seven ingredients each, the four most-listed ingredients, the absence of certificates of analysis, the missing FDA disclaimers, and the DSHEA swallowing requirement. Record confirmed via the EuropePMC REST API (PMID 41480958).
12. 12labelDailyMed — OZEMPIC (semaglutide) injection, prescribing information — Description section: molecular formula C187H291N45O59, molecular weight 4,113.58 g/mol, and the 31-amino-acid backbone. Also the subcutaneous route.
13. 13labelDailyMed — BUTRANS (buprenorphine) transdermal system, prescribing information — Description section: molecular weight of buprenorphine 467.6, empirical formula C29H41NO4 — the heaviest drug in our comparison table and still under the 500 Da line.
14. 14labelDailyMed — TRANSDERM SCOP (scopolamine) transdermal system, prescribing information — Description section: scopolamine molecular weight 303.35, empirical formula C17H21NO4.
15. 15labelDailyMed — VIVELLE-DOT (estradiol) transdermal system, prescribing information — Description section: estradiol molecular weight 272.39 g/mol, molecular formula C18H24O2.
16. 16govNCCIH — Berberine and Weight Loss: What You Need To Know — Source for the more-than-one-gram-a-day and more-than-eight-weeks finding, the high risk of bias in the underlying studies, the cyclosporine interaction, and the infant and pregnancy cautions.
17. 17govNCCIH — Green Tea: Usefulness and Safety — Source for the modest effect of catechins and caffeine on body weight, and for liver injury reported in some people using green tea extracts in tablet or capsule form.
18. 18govPubChem — Berberine (CID 2353) — Source for berberine at 336.4 g/mol. L-glutamine (CID 5961, 146.14) and cinnamaldehyde (CID 637511, 132.16) were read from the same PubChem property API.
19. 19labelDailyMed — MOUNJARO (tirzepatide) injection, prescribing information — Alopecia appears only in the postmarketing experience section under Skin and Subcutaneous Tissue, with the same frequency and causality caveat. Checked alongside the oral semaglutide label (setid 27f15fac), SAXENDA (3946d389) and VICTOZA (5a9ef4ea), each of which lists alopecia in postmarketing experience only.
20. 20studyTelogen Effluvium — StatPearls, NCBI Bookshelf (National Library of Medicine) — Excessive shedding of resting hair after metabolic stress, hormonal change or medication. Trigger list includes crash dieting, low protein intake, hypothyroidism and iron deficiency. A causative event is typically found about 3 months before onset, range 1 to 6 months; acute telogen effluvium lasts under 6 months by definition; the condition is described as benign and spontaneously reversible, with reassurance about recovery of hair density with time and nutritional support.
21. 21govNIH Office of Dietary Supplements — Biotin, consumer fact sheet — States that supplements containing biotin are often promoted to improve hair, skin and nail health but there is little scientific evidence to support these claims, and more research is needed before biotin can be recommended for any of these conditions. Also that biotin deficiency is very rare in the United States, and that biotin above recommended amounts may cause false results in some lab tests including thyroid hormone tests.
22. 22studyZambrano-Villacres et al., Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity, Nutrients (2026), PMC13258902 — Source of the protein range of approximately 1.2 to 1.6 g/kg/day adjusted for age, renal function and comorbidities, the statement that higher targets should not be applied in chronic kidney disease without individual clinical and dietetic assessment, and the point that obesity guidance commonly manages the rate of weight loss rather than maximising it.
23. 23gov · 2024FDA — Serving Size on the Nutrition Facts Label — Source for serving sizes reflecting what people typically consume rather than a recommendation of how much to eat.

The tag says what kind of source a link is; the year is the revision or publication year the page itself states, and is left off where the page states none. Every URL here was opened and read — a source list proves a page loads, not that it says what we claim, so we check the second part by hand.